NEW YORK (
CHANGE IN RATINGS
downgraded at Sterne Agee to Neutral, Sterne Agee said. Valuation call, based on a $52 price target.
upgraded at UBS to Buy from Neutral, UBS said. $99 price target. Upgrade to buy on PNH, NMO and margins.
upgraded to buy at TheStreet Ratings.
upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $33 price target. Industry is leveraged to better economic growth.
downgraded to sell at TheStreet Ratings.
upgraded at JP Morgan to Overweight, JP Morgan said. Expectations are low and the company has been gaining market share.
upgraded at Deutsche from Hold to Buy, Deutsche Bank said. Company is a market leader and the group appears more attractive.
( HGSI) downgraded at Collins Stewart from Buy to Neutral, Collins Stewart said. $10 price target. Benlysta sales could fall short of expectations.
rated new Hold at Stifel. Valuation cal.
upgraded at Wunderlich from Hold to Buy, Wunderlich said. $85 price target. Company should continue to deliver higher earnings and is trading at an attractive valuation.
downgraded at BofA/Merrill to Underperform, Bank of America/Merrill Lynch said. Valuation call, based on a $45 price target.
downgraded at FBR from Outperform to Market Perform, FBR Capital Markets said. $21 price target. Seeing more evidence of potential product delays.
upgraded at Deutsche to from Hold to Buy, Deutsche Bank said. Pringles purchase could prove to be an inflection point for the company. $57 price target.
upgraded at Morgan Stanley from Equal-weight to Overweight, Morgan Stanley said. $31 price target. Estimates also boosted, given higher secular demand.
downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. $100 price target. Valuation call, as the stock is up 96% since October.
upgraded at Sterne Agee from Neutral to Buy, Sterne Agee said. $35 price target. Company has solid long-term earnings growth potential.
downgraded at Feltl from Strong Buy to Buy, Feltl & Co. said. Recent guidance has been mixed.
upgraded at Brean Murray from Sell to Hold, Brean Murray said. Company will probably receive FDA approval for Qnexa in April.
STOCK COMMENTS / EPS CHANGES
numbers raised at Jefferies. Shares of AVGO now seen reaching $43, Jefferies said. Estimates also raised on good visibility into growth. Buy rating.
numbers reduced at Credit Suisse. Shares of AWAY now seen reaching $27, according to Credit Suisse. Estimates were also cut, as the company is spending more on potential growth. Neutral rating.
numbers raised at Jefferies. Shares of BLKB now seen reaching $28, Jefferies said. Estimates also raised on underlying trends. Hold rating.
target raised at to $15, UBS said. Target raised on near term momentum. Neutral rating.
numbers raised at JP Morgan. Shares of CLH now seen reaching $80, according to JP Morgan. Estimates also increased, as the company is executing well in a robust growth environment. Overweight rating.
estimates boosted at Morgan Stanley. CPB estimates were upped through 2014, Morgan Stanley said. Company is seeing better soup sales. Underweight rating and new $30 price target.
numbers increased at Guggenheim. DFS estimates were raised through 2013, Guggenheim said. Company is buying back more stock. Buy rating and new $34 price target.
numbers raised at UBS. Shares of FLR now seen reaching $71, UBS said. Estimates also raised on headwinds turning to tailwinds. Buy rating.
estimates upped at Morgan Stanley through 2014, Morgan Stanley said. Company has a new focus on increasing sales growth. Equal-weight rating.
estimates cut at Credit Suisse. HPQ estimates were reduced through 2013, Credit Suisse said. Company faces macro headwinds and lower services margins. Neutral rating and $30 price target.
numbers raised at UBS. Shares of NBR now seen reaching $24, UBS said. Estimates also raised as new CEO comes out of the gate strongly. Neutral rating.
numbers raised at UBS. Shares of TJX now seen reaching $39, UBS said. Estimates also raised as all engines at work to drive growth. Buy rating.
numbers raised at Oppenheimer. Shares of TPX now seen reaching $85, Oppenheimer said. Estimates also raised on upbeat analyst day. Outperform rating.
numbers raised at Jefferies. Shares of VVUS now seen reaching $11, Jefferies said. Estimates also raised on Qnexa approval. Underperform rating.
>To submit a news tip, email:
and become a fan on
This article was written by a staff member of TheStreet.